摘要
目的探讨非小细胞肺癌标本中MMP2和MMP9及VEGF的表达和意义。方法用免疫组化S-P法检测MMP2、MMP9、VEGF在77例肺癌组织中的表达。结果肺癌组织中MMP2、MMP9、VEGF主要表达于肿瘤细胞的胞浆,在癌旁交界区组织也有表达,肿瘤组织的过表达率显著高于交界区(P<0.05),MMP2、VEGF在肿瘤组织的过表达率与淋巴结转移状态、临床分期与原发肿瘤大小有关(P<0.05)。结论MMP2、MMP9、VEGF都参与了非小细胞肺癌发生发展过程,MMP2、VEGF在其中可能起到协同促进作用,MMP2、VEGF联合分析可能更有助于评估非小细胞肺癌患者的预后。
Objective To study the expression and significance of MMP2, MMP9 and VEGF in non-small cell lung carcinoma. Methods MMP2, MMP9 and VEGF expressions were determined in surgically treated 77 cases with non-small cell lung carcinoma tissues and their adjacent tissues. Results The immunoreactivities of MMP2, MMP9 and VEGF were mainly shown in cytoplasma of tumor cells. The overexpressions of MMP2, MMP9 and VEGF in carcinoma tissues were significantly higher than those in adjacent tissues（ P 〈 0. 05 ）. The overexpressions of MMP2 and VEGF in the cancer tissues were related to clinical stages, lymph node metastasis status and the size of primary cancer（P 〈 0. 05 ）. There was a trend that the survival rate of these patients with overexpression of MMP2 and MMP9, and VEGF was lower than that with non-overexpression, but there was no statistical significance. The survival rate of the group with both MMP2 and MMP9, and VEGF overexpressions was lower than that with non-overexpression （P 〈 0.05）. Conclusions MMP2,MMP9 and VEGF all take part in the progress of non-small cell lung carcinoma. We postulate that MMP2 can cooperate with VEGF in the processes. To investigate the over-expressions of both MMP2 and MMP9 in non-small cell lung carcinoma tissues may be more helpful for estimating the prognosis.
出处
《肿瘤基础与临床》
2007年第1期12-14,共3页
journal of basic and clinical oncology
关键词
非小细胞肺癌
基质金属蛋白酶
血管内皮生长因子
non-small cell lung carcinoma
matrix metalloproteinase
vascular endothelial growth factor
